Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
暂无分享,去创建一个
P. Richardson | H. van de Velde | P. Moreau | T. Facon | A. Perrot | Kenshi Suzuki | I. Špička | S. Macé | T. Martin | K. Bisht | M. Inchauspé | Kamlesh Bisht | F. Casca | H. V. D. van de Velde | I. Spicka
[1] J. Cowan,et al. Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy , 2021, Annals of Hematology.
[2] H. van de Velde,et al. Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies , 2021, Expert review of hematology.
[3] M. Dimopoulos,et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial , 2021, The Lancet.
[4] H. van de Velde,et al. Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics , 2021, British journal of haematology.
[5] A. Oriol,et al. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis , 2021, European journal of haematology.
[6] I. Hanamura. Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma , 2021, Cancers.
[7] M. Boccadoro,et al. Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial , 2020 .
[8] D. Wiederschain,et al. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells , 2020, Frontiers in Immunology.
[9] E. Tian,et al. Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome , 2019, British journal of haematology.
[10] M. Beksac,et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study , 2019, The Lancet.
[11] P. Richardson,et al. CD38 antibodies in multiple myeloma: back to the future. , 2018, Blood.
[12] P. Sonneveld,et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. , 2016, Blood.
[13] M. Dimopoulos,et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.
[14] Yongsheng Huang,et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. , 2006, Blood.
[15] V. Teplan,et al. [A new method to estimate glomerular filtration rate based on serum concentration of creatinine, urea and albumin (MDRD, Modification of Diet in Renal Disease)]. , 2004, Vnitrni lekarstvi.